BREAST CANCER DIAGNOSTIC MARKET ANALYSIS
Key Development
In September 2019, Todos medical Ltd., entered into a non-binding Memorandum of Understanding (MOU) with Orot+ to expand their existing launch and distribution partnership for the commercial sale of Todos TM-B1 and TM-B2 breast cancer detection blood tests in Japan.
In July 2019, Exact Sciences Corp and Genomic Health Inc. entered into a definitive agreement in which these companies will create a leading global cancer diagnostics company. The combined company will offer two of the strongest and fastest-growing brands in cancer diagnostics, Cologuard and Oncotype DX.
In July 2019, Paragon Biosciences launched the seventh portfolio company, Qlarity Imaging LLC, which was founded to harness the value of artificial intelligence (AI) to improve medical outcomes.
In 2016, Myriad Genetics acquired Sividon Diagnostics, a leading breast cancer prognostics company. This Acquisition enhances its competitive position in the oncology diagnostics market.
In 2015, BioNTech AG launched MammaTyper, a CE-IVD marked molecular diagnostic test to stratify breast cancer patients by molecular subtyping of routine tumor tissue.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
